No prob should get to it later this week. In general vaginal delivery is good when trying to direct meds to the uterus (there is a uterine first pass effect analagous to PO/liver). In the case of progesterone (crinone) it had the added benefit of avoiding injectable deliver until micronized progesterone became available, and even then the latter is limited by side effects (drowsiness) and gets metabolized into less active forms so correlation between progesterone levels and in situ activity poor (note synthetic progesterones are absorbed very well orally but are contraindicated in pregnancy)
crinone sales got hurt bc endometrin - another vaginal prog - came to market with a better label
edit: the crinone delivery vehicle also has a pretty significant yuck factor over time and looks like a yeast infection w thick white residue. This shouldn't be an issue for short term applications like topical anesthesia, which i see is in the pipeline on the website, for pre cervical/uterine procedures
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.